RCMP hampered by outdated technology and 'risk averse' culture: report - National Post

One of Australia’s top intelligence agencies has warned that AI attacks could exploit the country’s old technology, as the government negotiates its guardrails on artificial intelligence’s rapid development. The chief of Anthropic, developer of Claude, has warned AI bots could swarm the internet within a year and called to “slow the pace” of development with support from the head of OpenAI and Elon Musk. Abigail Bradshaw, the director general of the Australian Signals Directorate, said her agency did not know how many AI agents were active on the internet. “I think that prospect of getting some sort of definition or calculation of how these agents are out there is really remote,” Bradshaw said while speaking to the Sydney Dialogue summit in Canberra on Monday. “And I would just say: a lot.”She said Australian governments and businesses would have to spend “enormous” amounts to update their vulnerable outdated technology, taking offline systems that Australians had come to expect would be available all the time.

The investigational factor XI (FXI) monoclonal antibodies amrecibart and cenvacibart demonstrated successful anticoagulation with a favorable safety profile in preclinical and phase 1 clinical studies, representing a novel treatment strategy for patients with thrombosis. The results were published in Blood by Dan Chalothorn, PhD, of Regeneron Pharmaceuticals, and colleagues. The research team first compared the mechanisms and coagulation effects of amrecibart and cenvacibart with other FXI-targeted monoclonal antibodies in both human and nonhuman primate plasma using an in vitro functional clotting assay.1Targeting the Intrinsic PathwayWith unique FXI/FXIa-binding mechanisms, amrecibart and cenvacibart address an unmet need for novel treatments with a favorable risk-benefit profile because current standard-of-care anticoagulants carry a high risk for bleeding. Cenvacibart and amrecibart block FXI activity by targeting the catalytic domain and the apple 2 domain of FXI/FXIa, respectively. Although standard-of-care anticoagulants target the extrinsic coagulation pathway, these monoclonal antibodies specifically target the intrinsic coagulation pathway.